HYDROmorphone HCl 30 mg/30mL in 0.9% Sodium Chloride Injection, (Concentration = 1 mg/ml) 30 mL f...

FDA Drug Recall #D-0409-2024 — Class II — November 9, 2023

Recall Summary

Recall Number D-0409-2024
Classification Class II — Moderate risk
Date Initiated November 9, 2023
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm SCA Pharmaceuticals, LLC
Location Windsor, CT
Product Type Drugs
Quantity 5392 syringes

Product Description

HYDROmorphone HCl 30 mg/30mL in 0.9% Sodium Chloride Injection, (Concentration = 1 mg/ml) 30 mL fill 35 mL Plungerless Syringe, Rx only, SCA Pharmaceuticals, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0303-16, Bar Code 70004030316

Reason for Recall

Lack of Assurance of Sterility

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lot #: 1223048357 Exp 11/15/23; 1223048461 EXP 11/20/23; 1223048486 EXP 11/21/23; 1223048694 EXP 12/01/23; 1223048865 EXP 12/06/23; 1223048967 EXP 12/11/23; 1223049098 EXP 12/15/23; 1223049133 EXP 12/19/23; 1223049175 EXP 12/20/23; 1223049268 EXP 12/25/23; 1223049457 EXP 01/01/24; 1223049561 EXP 01/04/24; 1223049604 EXP 01/05/24; 1223049648 EXP 01/09/24; 1223049870 EXP 01/17/24; 1223049942 EXP 01/19/24; 1223049973 EXP 01/23/24; 1223050060 EXP 01/25/24;

Other Recalls from SCA Pharmaceuticals, LLC

Recall # Classification Product Date
D-0417-2024 Class II PHENYLephrine HCl 5000 mcg/50 mL in 0.9% Sodium... Nov 9, 2023
D-0399-2024 Class II fentaNYL 100 mcg/50 mL, Bupivacaine HCl 0.125% ... Nov 9, 2023
D-0411-2024 Class II labetalol HCl 20 mg/4mL Injection, (Concentrati... Nov 9, 2023
D-0410-2024 Class II HYDROmorphone HCl 30 mg/30 mL in 0.9% Sodium Ch... Nov 9, 2023
D-0419-2024 Class II PHENYLephrine HCl 40 mg in 0.9% Sodium Chloride... Nov 9, 2023

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.